Mancini Anthony sold $720K of RVMD

Mancini Anthony (See Remarks) sold 4,615 shares of Revolution Medicines, Inc. (RVMD) at $156.12 ($0.72M total) on 2026-06-16.

Original reporting
SEC EDGAR · Mancini Anthony
Published Jun 18, 2026, 8:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 18, 2026, 8:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$RVMD
Neutral
medium confidence
Mentioned
$RVMD
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RVMDNeutralLow
01

Why it matters

The newest fact is the disclosed open-market sale by an officer (Mancini Anthony) with exact shares, price, and post-transaction holdings; it may slightly affect sentiment but lacks fundamental drivers.

02

Market read

Traders may monitor for follow-on insider activity, but this single sale is usually not enough to reprice the stock without additional catalysts.

03

What to watch

The filing doesn’t state motivations (taxes, diversification, planned expenses) and provides no follow-on buying or company-specific news, limiting tradable inference.

Relevance 5/10Novelty 5/10Timing: Filed 2026-06-18; transaction dated 2026-06-16 (after-hours/next-session read-through).

Background

This is an SEC Form 4 insider transaction disclosure for Revolution Medicines, Inc. (RVMD).

Company-level read

Ticker impact

$RVMDNeutralMedium confidence
Context

Form 4 shows officer Mancini Anthony sold 4,615 RVMD shares on 2026-06-16 at $156.1192/share for ~$720.5K.

Expected impact

Likely limited near-term impact; any effect would be sentiment-only and typically fades unless paired with other negative disclosures.

Evidence & confidence

The article is a primary-source insider transaction with disclosed size and price, but it provides no guidance, operational change, or material event beyond the sale itself.

Market effects

Minimal; single-company insider sale without sector-wide signal.

None indicated.

None indicated.

Counterpoint

Insider sales are often pre-planned for liquidity/taxes; absence of a stated 10b5-1 plan doesn’t necessarily imply negative expectations.

Key entities

  • Revolution Medicines, Inc.

    Subject of the Form 4 insider sale disclosure.

  • Mancini Anthony

    Officer who sold 4,615 shares of RVMD on 2026-06-16.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RVMDMedAI 8/10

Why is Revolution Medicines stock surging today?

Revolution Medicines (RVMD) stock rose 7% after reporting Q3 revenue of $197.6M, exceeding estimates, driven by its new drug RASONQUE. Analysts raised price targets, with HC Wainwright setting a $350 target. The company has strong cash reserves and reaffirmed its 2026 expense guidance. NASDAQ and S&P 500 gains provided a supportive market backdrop.

$RVMDMed

Revolution Medicines Inc (RVMD) Q3 2026 Earnings Call Highlights: RASONQUE's Blockbuster

Revolution Medicines (RVMD) reported $198M in first-month sales for RASONQUE, with inventory levels managed at two weeks. Prescriptions were split 40% academic and 60% community. The company expects payer coverage to evolve, with reimbursement currently strong. RASonate 312 trial is ongoing, and the company is exploring broader colorectal cancer opportunities. Management declined to comment on October trends, citing early launch stage.

$RVMDHigh

Revolution Medicines (RVMD) Q3 2026 Earnings Call Transcript

Revolution Medicines (RVMD) reported $198M in Q3 2026 revenue from its newly approved drug, RAZONQ, for metastatic pancreatic cancer. The FDA approved the drug in August, and the NCCN guidelines expanded its recommended use. The company is preparing for international expansion and has received positive opinions from the EMA. RAZONQ is also being studied for non-small cell lung cancer.

$RVMDMed

What Revolution Medicines (RVMD) Said on Its Q3 Earnings Call

Revolution Medicines (RVMD) reported Q3 earnings, highlighting RASONQUE's reimbursement progress, regulatory updates, and pipeline advancements. RASONQUE is included in NCCN guidelines for pancreatic cancer. The company expects European and potential Japanese launches. Q3 revenue included initial stocking, with R&D expenses rising to $417.1M. RVMD ended the quarter with $3.7B in cash. The company reiterated 2026 operating expense guidance and anticipates higher 2027 expenses.

$RVMDHighAI 9/10

Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress

Revolution Medicines, Inc. (RVMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress · Received U.S. FDA approval and launched RASONQUE® (daraxonrasib) for adult patients with metastatic pancreatic cancer who have received at least one prior systemic th